PT  - JOURNAL ARTICLE
AU  - Majmundar, Monil
AU  - Kansara, Tikal
AU  - Lenik, Joanna Marta
AU  - Park, Hansang
AU  - Ghosh, Kuldeep
AU  - Doshi, Rajkumar
AU  - Shah, Palak
AU  - Kumar, Ashish
AU  - Amin, Hossam
AU  - Habtes, Imnett
TI  - Efficacy of Corticosteroids in Non-Intensive Care Unit Patients with COVID-19 Pneumonia from the New York Metropolitan region
AID  - 10.1101/2020.07.02.20145565
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.02.20145565
4099  - http://medrxiv.org/content/early/2020/07/04/2020.07.02.20145565.short
4100  - http://medrxiv.org/content/early/2020/07/04/2020.07.02.20145565.full
AB  - Introduction The role of systemic corticosteroid as a therapeutic agent for patients with COVID-19 pneumonia is controversial.Objective The purpose of this study was to evaluate the effect of corticosteroids in non-intensive care unit (ICU) patients with COVID-19 pneumonia complicated by acute hypoxemic respiratory failure (AHRF).Methods This was a single-center retrospective cohort study, comprising of 205 patients admitted to the general wards with COVID-19 pneumonia. The primary outcome was a composite of ICU transfer, intubation, or in-hospital mortality. Cox-proportional hazard regression was implemented.Result Among 205 patients, 60 (29.27%) were treated with corticosteroid. The mean age was ∼57 years, and ∼75% were men. Thirteen patients (22.41%) developed a primary composite outcome in the corticosteroid cohort vs. 54 (37.5%) patients in the non-corticosteroid cohort (P=0.039). The adjusted hazard ratio (HR) for the development of the composite primary outcome was 0.15 (95% CI, 0.07 – 0.33; P <0.001). The adjusted hazard ratio for ICU transfer was 0.16 (95% CI, 0.07 to 0.34; P < 0.001), intubation was 0.31 (95% CI, 0.14 to 0.70; P – 0.005), death was 0.53 (95% CI, 0.22 to 1.31; P – 0.172), and discharge was 3.65 (95% CI, 2.20 to 6.06; P<0.001). The corticosteroid cohort had increasing SpO2/FiO2 over time compared to the non-corticosteroid cohort who experience decreasing SpO2/FiO2 over time.Conclusion Among non-ICU patients hospitalized with COVID-19 pneumonia complicated by AHRF, treatment with corticosteroid was associated with a significantly lower risk of the primary composite outcome of ICU transfer, intubation, or in-hospital death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external or internal funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Brany IRB and Star NYCHHC approval takenAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot available given the identifiable nature of the datasetCOVID-19Coronavirus disease 2019AHRFAcute Hypoxemic Respiratory FailureICUIntensive Care UnitSF ratioSpO2/FiO2 ratio